Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

These six pharmaceutical/biotech stocks have been pegged as the worst performers coming out of the market's COVID lows. Three of the six laggards - Gilead, Biogen, and Regeneron - have a disease area in which they excel with compelling plans for ancillary growth.

On Sale: Glitter From The Healthcare Wreckage, Biotech Edition

SAGE Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study (n=67 full analysis set) achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo in The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale Item 4 upper limb tremor score on Day 2

Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

iTeos Therapeutics, Inc.

Novavax

Upcoming events could send these stocks screaming higher or lower.

3 Biotech Stocks With Big Catalysts Around the Corner

Apple

Alibaba

Intel

A few months ago, GuruFocus launched the "baskets" feature, which allows users to place stocks in one of four virtual baskets based on their level of interest:

Top Stocks That GuruFocus Users Are Looking At

AbbVie

ACADIA Pharma

Alexion Pharma

AstraZeneca

BioNTech SE

CRISPR Therapeutics

Editas Medicine

Illumina

Kadmon Hlds

Moderna

Pfizer

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.

Biotech Stocks Could Use A Win — Will The First Quarter Offer That?

Biogen Inc (NASDAQ: BIIB) and Bio-Thera Solutions Ltd have entered into a commercialization and license agreement to develop, manufacture, and commercialize BAT1806, a proposed biosimilar referencing Genentech's Actemra (tocilizumab). The anti-interleukin-6 (IL-6) receptor monoclonal antibody is currently in a Phase 3 study.

Biogen, Bio-Thera Ink Licensing Agreement For Development Of Actemra-Based Biosimilar For Rheumatoid Arthritis

CAMBRIDGE, Mass. and GUANGZHOU, China, April 08, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a Phase 3 clinical stage anti-interleukin-6 (IL-6) receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA® 1 (tocilizumab).

Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis

CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of TYSABRI® (natalizumab) to treat relapsing-remitting multiple sclerosis (MS). The new route of administration offers comparable efficacy and safety to the TYSABRI intravenous (IV) formulation building on the therapy's long-term data, established clinical benefits and well-characterized safety profile. TYSABRI is the only high-efficacy MS therapy to offer two routes of administration options providing patients and physicians the flexibility to choose the one that best fits their individual needs.

The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis

Experts worry about how trial data was analyzed.

Is This Another Strike Against Biogen's Alzheimer's Drug?

Biogen Inc.'s (NASDAQ:BIIB) management and shareholders are keeping their fingers crossed that the Food and Drug Administration rules favorably on the company's controversial Alzheimer's drug. The decision on what BioPharma Dive called "the most closely watched drug in all biotech" is expected by the first week in June.

FDA's Decision on Biogen Alzheimer's Drug Expected in June

Biogen's future isn't only wrapped up in Alzheimer's treatment aducanumab, an analyst said Thursday. He identified two low-probability events that could stoke Biogen stock.

Two Things That Could Stoke Biogen Stock — That Aren't Aducanumab

Fate Therapeutics

Johnson & Johnson

Orchard Therapeutics plc - ADR

Sana Biotechnology

Sangamo Therapeutics

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Regenerative Medicine Attracted Record $20 Billion in Funding in 2020

D.R. Horton

Turtle Beach

Seneca Foods

Oppenheimer Holdings

Surface Oncology Inc

It's been a long time coming, but the great value comeback appears to be underway.

6 Stocks to Play the Value Revival

They're making headway into tomorrow's hot markets.

Got $5,000? Consider These 3 Leading Pharma Stocks

They'll determine short-term and long-term stock performance.

Before You Buy Biogen, Stop and Consider These 3 Things

Cooper Companies

Humana

Universal Health Services

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have grown their book value per share over the past decade through March 11.

4 Health Care Stocks Boosting Book Value

Honda

Toyota Motor

Vale S.A.

These 4 stocks to buy have good fundamentals, are attractive from a valuation perspective and can provide safety in a volatile 2021. The post 4 Stocks To Buy Ready To Bounce Back From 2020's Dumpster Fire appeared first on InvestorPlace.

4 Stocks To Buy Ready To Bounce Back From 2020's Dumpster Fire

A controversial Alzheimer's drug that has weighed on Biogen stock this year could ultimately become a major blockbuster within five years, a market research group predicted Tuesday. The post Why A Controversial Biogen Drug Could Become A Major Blockbuster appeared first on Investor's Business Daily.

Why A Controversial Biogen Drug Could Become A Major Blockbuster

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?

Biogen Inc. (BIIB) Down 1.4% Since Last Earnings Report: Can It Rebound?

Biogen Inc (NASDAQ: BIIB) plans to build a new gene therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina to support its growing gene therapy pipeline, with an estimated total investment of approximately $200 million. Biogen aims to continue its investment in North Carolina through the new facility and expand its existing operations and a combined workforce of approximately 1,900 employees at both campuses in Research Triangle Park.

Biogen To Build New Gene Therapy Facility With $200M Investment

Shares of Biogen Inc. were down 0.2% in premarket trading on Thursday after the company said it plans to build a gene therapy manufacturing site at its campus in Research Triangle Park region in North Carolina. Biogen expects to offer 90 new jobs at the new facility, which was a total investment of $200 million for the drug maker.

Biogen to build gene therapy manufacturing center in North Carolina

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufacturing campuses in North Carolina to support its growing gene therapy pipeline across multiple therapeutic areas.

Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina

Charter Communications

eBay

Alphabet

Lowe's

Microsoft

Oracle

Very little gets past Warren Buffett when it comes to investing. But even he seems genuinely amazed how stock buybacks are a "costless" way to make money.

8 Stocks Use Warren Buffett's 'Costless' Trick To Make Money

News for Biogen Stock (BIIB)